To consider approve and adopt The Standalone and consolidated Audited Financial Results for the Quarter and Financial year ended March, 31 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals' Board, on May 30, 2025, approved its audited standalone and consolidated financial results for Q4 and FY25. Standalone revenue from operations grew 30% year-on-year to Rs. 45,170.62 lakhs (vs Rs. 34,657.69 lakhs in FY24), while net profit rose 33% to Rs. 2,080.76 lakhs (vs Rs. 1,562.34 lakhs), lifting EPS to Rs. 44.83 from Rs. 33.66. The Board recommended a 7% final dividend on equity shares of Rs. 10 face value, pending shareholder approval at the 38th AGM. Statutory auditor R.H. Nisar & Co. issued an unmodified (clean) opinion on both sets of results. Two new subsidiaries — Fredun Retail Pvt Ltd and One Pet Stop Pvt Ltd — were consolidated for the first time. The auditor flagged delays in transferring unclaimed dividends and shares to the IEPF as an Other Matter.
Strong top-line and earnings growth, along with the dividend, are positive signals for shareholders. However, the jump in trade receivables (nearly 3x to Rs. 17,712 lakhs) and short-term borrowings (up ~70% to Rs. 15,679 lakhs), combined with deeply negative operating cash flow of Rs. (2,888) lakhs, suggests growth is being funded by debt and working capital stretch — watch for further disclosures on receivables quality and debt servicing.